Rio Tinto Raises 2025 Copper Output Outlook as Oyu Tolgoi Expansion Accelerates 
Netflix Nearing Major Deal to Acquire Warner Bros Discovery Assets 
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options 
UPS MD-11 Crash Prompts Families to Prepare Wrongful Death Lawsuit 
FDA Names Tracy Beth Høeg as Acting CDER Director After Richard Pazdur Announces Retirement 
Germany’s Economic Recovery Slows as Trade Tensions and Rising Costs Weigh on Growth 
GM Issues Recall for 2026 Chevrolet Silverado Trucks Over Missing Owner Manuals 
Merck Nears Acquisition of Cidara Therapeutics at Significant Premium 
Proxy Advisors Urge Vote Against ANZ’s Executive Pay Report Amid Scandal Fallout 
Trump Signs Executive Order to Boost AI Research in Childhood Cancer 
Pfizer Secures $10 Billion Deal for Obesity Drug Developer Metsera, Outbids Novo Nordisk 
Wikipedia Pushes for AI Licensing Deals as Jimmy Wales Calls for Fair Compensation 
Hikvision Challenges FCC Rule Tightening Restrictions on Chinese Telecom Equipment 
U.S. Futures Steady as Rate-Cut Bets Rise on Soft Labor Data 
Innovent’s Xinermei Intensifies Weight-Loss Drug Battle in China 
IKEA Expands U.S. Manufacturing Amid Rising Tariffs and Supply Chain Strategy Shift 
South Korean pharmaceutical and biotech companies are collaborating to develop new drugs using artificial intelligence (AI).
AI can predict whether a chemical compound is suitable for human use, thereby speeding up the identification of potential substances and enabling the selection of appropriate clinical patients.
There are over 100 cases where candidate substances for new drugs are under development using AI, with over 50 percent carried out through collaborations between domestic and foreign companies, according to the Korea Pharmaceutical and Bio-pharma Manufacturers Association.
HK inno.N Corp. and AinB recently signed an MOU to identify a new antibody candidate substance for cell and gene therapies and establish an antigen design platform for vaccine development.
Last year, Pharos iBio inked a deal with Yuhan Corp. to promote the joint study and technology transfer of the AI-based KRAS inhibitor.
This company is now carrying out a phase 1 clinical trial in Korea and Australia after developing PHI-101, a candidate substance for the treatment of leukemia, using its AI platform, Chemiverse.
Moreover, Oncocross, which has AI technology to identify the optimal disease for drugs, signed a joint study and development contract with Boryung Corp. in February to expand the indications of hypertension treatment.
